Skip to main content

Posts

Showing posts with the label Infosys Technologies

Infosys Q3 results beat expectations

I nfosys Technologies has reported a 3.6 per cent YoY decline in net profit to Rs 1,582 crore for the third quarter ended December 31, 2009. Total income too saw a decline of close to 1 per cent to Rs 5,741 crore. On a sequential basis, net profit grew by 2.7 per cent while the topline by 2.8 per cent, indicating some silver lines as the economy is trying to pull itself away from the recessionary quicksand. Earnings per share decreased to Rs. 27.75, showing a 3.2 per cent decline yoy and a 3.3 per cent growth on a sequential quarter basis. The company has said that going forward the EPS for the fourth quarter is expected to fall in the range of 8.3 to 9 per cent, while for the entire year there will be a marginal growth of around 2.5 per cent.

Infosys Q2 net up 7.5% at Rs 1,540 cr

Infosys Technologies on Friday reported 7.54 per cent rise in consolidated net profit after tax at Rs 1,540 (Rs 1,432 second quarter of last fiscal) crore for the quarter ended September 30, 2009. “In the second quarter, the business climate has improved,” Mr S Gopalakrishnan, CEO and Managing Director, Infosys said. Total income stood at Rs 5,821 crore, showing an over six per cent rise, at the end of the September quarter of the current fiscal. The board declared an interim dividend of 200 per cent at the rate of Rs 10 a share. The company added 35 new clients during the quarter.

Todays Pick from the Newspapers

The Hindu Business Line Pfizer (Rs 632.90): Buy We recommend a buy in Pfizer from a short-term perspective. From the chart, we see that it had been on a medium-term downtrend from December 2007 high of Rs 850 to mid-February low of Rs 587. However, the stock’s medium-term downtrend got ... More The Economic Times Stocks to pick: SBI, Infosys Technologies, Crompton Greaves, GLaxosmithkline State Bank of India Research: HSBC Rating: Underweight CMP: Rs 2,115 Infosys Technologies Research: Indiabulls Financials Rating: Buy CMP: Rs 1,580 Crompton Greaves Research: JM Financials Rating: Buy CMP: Rs 298 GLaxosmithkline Pharma Research: Motilal Oswal Rating: Buy CMP: Rs 953